Mechanisms of mycobacterial drug resistance: Implications for treatment and prevention strategies

Chemotherapie Journal

Volumn 15, Issue 2, 2006, Pages 23-28

  Böttger, Erik C ^a,b  

^a Universität Zürich ^*

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Fitness; Prevention; Resistance; Susceptibility testing; Treatment; Tuberculosis

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; MACROLIDE; PYRAZINAMIDE; QUINOLONE; RIFAMPICIN; STREPTOMYCIN;

MYCOBACTERIUM TUBERCULOSIS; REVIEW; SHORT COURSE THERAPY; TUBERCULOSIS;

EID: 33645916397     PISSN: 09406735     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Andersson DI, Levin BR. The biological cost of antibiotic resistance. Curr Opin Microbiol 1999;2:489-93.
2. Austin DJ, Andersson RM. Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models. Philos Trans R Soc Lond B Biol Sci 1999;354:721-38.
3. Besier S, Ludwig A, Brade V, Wichelhaus TA. Compensatory adaptation of the loss of biological fitness associated with acquisition of fusidic acid resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:1426-31.
4. Billingon OJ, McHugh TD, Gillespie SH. Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999;46:1866-9.
5. Björkholm B, Sjölund M, Falk PG, Berg OG, et al. Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori. Proc Natl Acad Sci 2001;98:14608-12.
6. Bjorkman J, Hughes D, Andersson DI. Virulence of antibiotic-resistant Salmonella typhimurium. Proc Natl Acad Sci 1998;95: 3949-53.
7. Bjorkman J, Nagaev I, Berg OG, Hughes D. et al. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 2000;287:1479-82.
8. Bodmer T, Zürcher G, Imboden P, Telenti A. Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycin and rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1995;35:345-8.
9. Bouger EC. Drug resistant tuberculosis. Lancet 2001;357:1288-9.
10. Böttger EC, Pletschette M, Andersson D. Drug resistance and fitness in Mycobacterium tuberculosis infection. J Infect Dis 2005;191: 823-4.
11. Böttger EC, Springer B, Pletschette M, Sander P. Fitness of antibiotic-resistant microorganisms and compensatory mutations. Nat Med 1998;4:1343-4.
12. Canetti G. Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis 1965;92:687-703.
13. Canetti G, Fox W, Khomenko A, Mahler HT, et al. Advances in technique of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969;41:21-43.
14. Cohn M, Kovitz C, Oda U. Studies on isoniazid and tubercle bacilli: the growth requirements, catalase activities, and pathogenic properties of isoniazid resistant mutants. Am Rev Tuberc 1954;70:641-64.
15. Espinal MA, Kim SI, Suarez PG, Kam KM, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcome in 6 countries. JAMA 2000;283:2537-45.
16. Heym B, Stravropoulos E, Hononré N, Domenech P, et al. Effects of overexpression of the alkyl hydroperoxide reductase AhpC on the virulence and isoniazid resistance of Mycobacterium tuberculosis. Infect Immun 1997;65: 1395-401,
17. Inderlied CB, Salfinger M. Antimicrobial agents and susceptibility tests: mycobacteria. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, et al. (eds.). Manual of clinical microbiology. Washington, D.C.: American Society for Microbiology, Press, 1995:1385-404.
18. Maisnier-Patin S, Berg OG, Liljas L, Andersson DI. Compensatory adaptation to the deleterious effect of antibiotic resistance in Salmonella typhimuri. Mol Microbiol 2002;46:355-66.
19. Meier A, Sander P, Schaper K-J, Scholz M, et al. Correlation of molecular resistance mechanism and phenotypic resistance level in streptomycin resistant M. tuberculosis. Antimicrob Agents Chemother 1996;40:2452-4.
20. Nagaev I, Björkman J, Andersson DI, Hughes D. Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol Microbiol 2001;40:433-9.
21. Pym AS, Saint-Joanis B, Cole ST. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun 2002;70:4955-60.
22. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998;79:3-29.
23. Sander P, Springer B, Prammananan T, Sturnfels A, et al. Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob Agents Chemother 2002;46:1204-11.
24. Sander P, Böttger EC. Mycobacteria: genetics of resistance and implications for treatment. Chemotherapy 1999;45:95-108.
25. Sander P, Meier A, Böttger EC. Mechanisms of drug resistance in mycobacteria: macrolides and aminoglycosides. Res Microbiol 1996;147:59-67.
26. Schrag SJ, Perrot V. Reducing antibiotic resistance. Nature 1996;381:120-1.
27. Schrag SJ, Perrot V, Levin BR. Adaptation to the fitness cost of antibiotic resistance in Escherichia coli. Proc Biol Sci 1997;264: 1287-91.
28. Sherman DR, Mdluli K, Hickey MJ, Arain RM, et al. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 1996;272:1641-3.
29. Springer B, Master S, Sander P, Zahrt T, et al. Silencing of oxidative stress response in Mycobacterium tuberculosis: expression patterns of ahpC in virulent and avirulent strains and effect of ahpC inactivation. Infect Immun 2001;69:5967-73.
30. van Soolingen D, Borgdorff MW, de Haas PE, et al. Molecular epidemiology of tuberculosis in the Netherlands: a nationwide study from 1993 through 1997. J Infect Dis 1999;180: 726-36.
31. van Soolingen D, de Haas PE, van Doorn HR, Kuijper E, et al. Mutations at amino-acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J Infect Dis 2000;182:1788-90.
32. Yang B, Koga H, Ohna H, Ogawa K, et al. Relationship between antimicrobial activities of rifampicin, ribabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrob Chemother 1998;42:621-8.